582P - Cardioprotective effects of pentoxifylline on ventricular fibrillation and fibrosis in rat model of radiation-induced heart abnormalities

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Cancer Biology
Presenter afsaneh Safaie
Citation Annals of Oncology (2016) 27 (suppl_9): ix1-ix8. 10.1093/annonc/mdw573
Authors A.M. Safaie, E. Esmati
  • Institute Cancer, Central Cancer Institute of Imam Khomeini Hospital, 1419764531 - Tehran/IR



Recent technologies of cancer radiotherapy have enhanced the survival rate of patients in the last decades. However, radiation exposure may increase the risk of the side effects in cancer therapy, typically, enhancement of the heart fibrosis and infarction. Radiation-induced heart abnormalities (RHAs) can appear as long-term side effects when all or even a part of the heart are influenced by radiation in breast or lung cancer patients.


Thirty-four rats were randomly divided into four groups: (I) control (n = 5); healthy animals without any manipulation, (II) radiation (n = 7); animals underwent irradiation for 5 sessions for a total dose of 1200 centigray gamma-rays for two weeks, (III) PTX (n = 11); animals treated with PTX (95-105 mg/kg/day) which added to drinking water with Vit E (5.5 mg/kg/day, i.p) for 6 weeks.


Key findings: RAD decreased significantly heart rate, force of contraction, LVDP RPP, +dP/dt max and −dP/dt min, but increased dramatically LVEDP compared with the control group, and PTX significantly restored these parameters. RAD caused an increase in VF by decreasing its threshold. The lung and heart fibrosis changes have appeared in radiated animals, after 27 weeks irradiation which was reversed by PTX. Immunohistochemistry examinations of the heart sections showed high Bax and low Bcl-2 expressions in RAD and PTX groups compared with control.


Significance: The present study shows that pre-treatment withPTX in radiation-induced heart abnormalities can decrease fibrosis and VF. The findings suggest that PTX has an impactful protective effect on heart abnormalities.

Clinical trial indentification

Legal entity responsible for the study

Emam Khomeini Hospital, Research Center, Institute Cancer


Emam Khomeini Hospital, Research Center, Institute Cancer


All authors have declared no conflicts of interest.